Clinical Trial Update: REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER

View source ↗

Summary

Clinical trial update showing real-world use of durvalumab in extensive-stage small cell lung cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Small Cell Lung Carcinoma | Status: COMPLETED